当前位置: 首页 >> 检索结果
622. Letter by Wang et al Regarding Article, "Impact of Heart Transplant Allocation Changes on Waitlist Mortality and Clinical Practice in Pediatric and Adult Patients With Congenital Heart Disease and Cardiomyopathy".624. Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation.
作者: Sara Moura-Ferreira.;Nicola Riccardo Pugliese.;Mauricio Milani.;Stefano Taddei.;Annemie Jacobs.;Nicolò De Biase.;Sebastiaan Dhont.;Maarten Falter.;Youri Bekhuis.;Wouter L'Hoyes.;Sarah Hoedemakers.;Steven Droogmans.;Bernard Cosyns.;Ruta Jasaityte.;Guido Claessen.;Lavinia Del Punta.;Lieven Herbots.;Marco De Carlo.;Matteo Mazzola.;Philippe B Bertrand.;Giosuè Falcetta.;Philippe Debonnaire.;Stefano Masi.;Jan Verwerft.
来源: Circulation. 2025年152卷23期1594-1607页
Managing clinically significant primary mitral regurgitation is challenging. Right ventricular-pulmonary arterial coupling, assessed with tricuspid annular plane systolic excursion (TAPSE) and systolic pulmonary artery pressure (sPAP) ratio, reflects right ventricular adaptability to afterload. This international multicenter cohort study aimed to evaluate the prognostic value of rest TAPSE/sPAP and exercise TAPSE (exTAPSE)/sPAP in primary mitral regurgitation.
625. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.
作者: Victorien Monguillon.;Peter J Kelly.;Michelle L O'Donoghue.;Jeong-Gun Park.;Erin A Bohula.;Jeffrey L Saver.;Dan Atar.;Anthony C Keech.;Peter S Sever.;Huei Wang.;Gabriel Paiva da Silva Lima.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2026年153卷2期86-93页
Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear.
626. Safety and Feasibility of Magnetic Resonance Imaging Within the First Week Following Transvenous Pacing System Implantation.
作者: Jonathan Raby.;Benjamin Bussmann.;Pok-Tin Tang.;C Fielder Camm.;Dimitrios Panagopoulos.;Hongyan Tao.;Jennifer J Rayner.;Timothy R Betts.;Matthew Ginks.;Julian Ormerod.;James Gamble.;Michala Pedersen.;Shawn Morais.;Kim Rajappan.;Stefan Neubauer.;Oliver J Rider.;Neil Herring.;Andrew J M Lewis.
来源: Circulation. 2025年152卷19期1393-1395页 628. Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction.
作者: Nandan Kodur.;Paul Gunsalus.;Alex Milinovich.;Jarrod E Dalton.;W H Wilson Tang.
来源: Circ Heart Fail. 2025年18卷11期e013386页
There are currently no robust clinical markers for assessing prognosis in patients with heart failure (HF) with recovered left ventricular ejection fraction (LVEF). This study sought to investigate whether NT-proBNP (N-terminal pro-B-type natriuretic peptide) measured at the time of LVEF recovery is an independent predictor of prognosis among patients with HF with recovered LVEF.
629. Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients With Chronic Kidney Disease.
作者: Xisheng Li.;Nikhil Raisinghani.;Alex Gallinat.;Carlos G Santos-Gallego.;Shihong Zhang.;Sabrina La Salvia.;Seonghun Yoon.;Hayrettin Yavuz.;Anh Phan.;Alan Shao.;Michael Harding.;David Sachs.;Carol J Levy.;Navneet Dogra.;Rupangi Vasavada.;Nicole C Dubois.;Uta Erdbrügger.;Susmita Sahoo.
来源: Circulation. 2026年153卷2期94-114页
Cardiovascular disease causes >50% of deaths in patients with advanced chronic kidney disease (CKD). Clinical studies suggest that kidney-derived factors contribute to cardiovascular disease development in CKD, independently of comorbidities. However, to date, no kidney-specific humoral risk factor that triggers direct cardiotoxicity has been identified. In this cross-sectional study, we investigate how, in patients with CKD, circulating extracellular vesicles (EVs) facilitate pathological kidney-heart communication, thereby causing cardiotoxicity, impairing cardiac function, and contributing to heart failure progression.
630. Multiparametric Contrast-Free MRI Successfully Identifies Venous Thrombus Responsive to Lytic Therapy: From Mice to Humans.
作者: Justinas Silickas.;Alberto Smith.;Marcelo E Andia.;René M Botnar.;Bijan Modarai.;Narayan Karunanithy.;Ashish S Patel.;Stephen Black.;Prakash Saha.;Alkystis Phinikaridou.
来源: Circ Cardiovasc Imaging. 2025年18卷11期e018175页
Randomized trials of venous thrombolysis to prevent postthrombotic syndrome have produced mixed results. A method to identify patients most likely to benefit from interventional treatment is needed. This study evaluated a contrast-free, magnetic resonance-based multisequence thrombus imaging (MSTI) technique to characterize deep venous thrombi and predict susceptibility to thrombolysis.
631. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.
作者: Robin Myte.;Andrea Mattsson.;Matt Poole.;Dustin J Little.;Per Nyström.;Alasdair Henderson.;Brian L Claggett.;Samvel B Gasparyan.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2025年18卷12期e013496页
Patients with cardiovascular conditions like heart failure (HF) often exhibit significant heterogeneity of the risk of clinical events. In clinical trials, large risk heterogeneity can result in an underestimation of treatment effects derived from Cox proportional hazards models. This occurs due to selection bias when estimating the hazard ratio, stemming from a disproportionate reduction of event-free patients in the control group compared with an effective active group over time, ultimately reducing the statistical power. Therefore, it is important to explore alternative analysis methods for outcome trials that are robust with respect to risk heterogeneity.
632. Uptake, Geographic Access, and Outcomes of Transcatheter Mitral Valve Repair in the United States.
作者: Atsuyuki Watanabe.;Hiroki A Ueyama.;Yoshihisa Miyamoto.;Hiroshi Gotanda.;Tsuyoshi Kaneko.;Azeem Latib.;Dhaval Kolte.;Suzanne J Baron.;Eric Secemsky.;Roger J Laham.;Yusuke Tsugawa.;Toshiki Kuno.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷12期e012134页
The dissemination of novel procedures should attempt to strike a balance between access and procedure quality. This study aimed to evaluate the temporal trends and geographic dispersion of mitral transcatheter edge-to-edge repair (M-TEER) sites and to examine the associations of site volume and site-to-population density with patient outcomes.
633. Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay.
作者: Robert S Kristiansson.;Douglas Spangler.;Wilhelm Linder.;Ulrika Winblad.
来源: Circ Heart Fail. 2025年18卷12期e012567页
Patients with heart failure tend to experience higher rates of hospital readmissions compared with other ambulatory care-sensitive conditions. In Sweden, the nationwide Care Coordination Act (CCA) was introduced in January 2018 with the goal of improving care coordination, resulting in a reduction of readmissions and length of stay. There is insufficient knowledge regarding the effect of this reform on patients with heart failure.
635. Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination.
作者: Silvia Fanti.;Carlene Dyer.;Inga Jóna Ingimarsdóttir.;Daniel Harding.;Guosu Wang.;Antonio D'Amati.;Eriomina Shahaj.;Adalbjorg Ýr Sigurbergsdóttir.;Helga Thórsdóttir.;Oddný Brattberg Gunnarsdóttir.;Stavroula Kanoni.;Paul Wright.;John Martin.;Jamie Chorlton.;Zoe Hollowood.;Siggeir Fannar Brynjólfsson.;Bjorn Rúnar Lúdvíksson.;Egle Solito.;Serena Bert.;Jack M Keane.;Saidi A Mohiddin.;M Paula Longhi.;Federica M Marelli-Berg.
来源: Circulation. 2025年152卷21期1485-1500页
The COVID-19 pandemic, caused by SARS-CoV-2, has led to the first approval of mRNA vaccines in humans. By producing the full-length SARS-CoV-2 Spike protein, they induce protective antiviral immunity. Acute myopericarditis (AMP) development after vaccination has repeatedly been reported; however, the pathogenesis of this complication remains elusive.
636. Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function.
作者: Xiaozhu Zhou.;Carsten Kuenne.;Stefan Günther.;Ilka Wittig.;Beyza Güven.;Doha Boutguetait.;Fredy Delgado Lagos.;Nadja Sachs.;Lars Maegdefessel.;Oliver J Müller.;Christian Münch.;Stefan Offermanns.;Ingrid Fleming.;Mauro Siragusa.
来源: Circulation. 2025年152卷25期1781-1799页
Nitric oxide (NO), generated by the endothelial NO synthase (eNOS), regulates vascular tone and endothelial homeostasis to counteract vascular inflammation. Most eNOS is localized at the cell membrane or in the Golgi apparatus, but the enzyme is also present in the endothelial cell nucleus. Here, we assessed the relevance of nuclear eNOS and NO signaling for endothelial cell function.
637. IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis.
作者: Zhongshan He.;Yaoyao Luo.;Zhonghui Duan.;Bin Su.;Wanqin Zeng.;Yu Guo.;Yongjiang Li.;Xi He.;Haixing Shi.;Zhuoming Zhou.;Chunling Jiang.;Duotian Qin.;Ji Zhang.;Yan Kang.;Wei Chen.;Xiangrong Song.
来源: Circulation. 2025年152卷22期1564-1581页
Impaired efferocytosis of macrophages within advanced atherosclerotic plaques leads to plaque deposition and rupture, ultimately resulting in atherothrombotic events. Effective restoration of efferocytic capacity in lesional macrophages remains a challenge in atherosclerosis treatment.
640. CKAP4 Promotes Atrial Fibrosis and Enhances Atrial Fibrillation Vulnerability via WNT/β-Catenin Activation.
作者: Yuntao Feng.;Zhisong Chen.;Yanhua Gao.;Xuebo Liu.;Hongwei Tan.
来源: Circ Arrhythm Electrophysiol. 2025年18卷11期e014217页
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, characterized by atrial fibrosis, a crucial substrate facilitating its initiation and persistence. CKAP4 (cytoskeleton-associated protein 4) has been associated with fibroblast activation; however, its involvement in atrial remodeling and AF susceptibility remains unclear.
|